Cardiovascular diseases, the who data
Cardiovascular diseases, the who data
Ginagamit ito bilang biologically active na pampadagdag sa pagkain — dagdag na pinagmumulan ng mga bitamina — B2, B6, C, mga organikong asido — mansanas, succinic, glutamine. Mga sangkap: malic acid, succinic acid, glutamic acid, badan extract, ascorbic acid, bitamina B2, B6.
УЗНАТЬ ПОДРОБНЕЕ >>>
I am happy to offer you a scientific Text on the topic of cardiovascular diseases: data from the WHO to English: Cardiovascular diseases: An analysis of data from the world health organization (WHO) Cardiovascular disease (CVD) is the leading cause of death and are associated with significant socio-economic costs. According to the latest data from the world health organization (WHO) died in the year 2019, approximately 17.9 million people HKE — the equivalent of around 32% of all deaths worldwide. These Figures among the global importance of these diseases and the need for effective prevention and treatment strategies for stress. Epidemiological Overview The WHO divided cardiovascular including diseases in several main forms: coronary heart disease (CHD), Stroke, Heart failure, rheumatic heart diseases, as well as other vascular diseases. Particularly alarming is that 85% of deaths occur due to CVD in countries with low or middle-income. This shows a clear social inequality in terms of access to medical care and prevention options. Risk factors According to WHO Reports, the following modifiable risk factors for the development of CVD is of particular importance: Tobacco, unhealthy diet, lack of physical activity, excessive consumption of alcohol, High blood pressure, Hypercholesterolemia, Diabetes mellitus. In addition to modifiable factors such as age, gender, and genetic predisposition play an important role. The risk for CVD increases significantly after the age of 40. Age, and men are affected in younger age groups more often than women. Geographical Distribution The WHO data also show significant regional differences: In Europe and North America, the mortality rate from CVD has decreased in the last decades due to better prevention, early diagnosis and advanced treatment methods. In Africa, Southeast Asia and the Region of the Western Pacific, however, the burden of CVD is increasing continuously. Prevention strategies and recommendations of the WHO The global burden of cardiovascular reduce disease, the WHO suggests several measures: Strengthening primary prevention through health-promoting policies (e.g., tobacco control laws, salt reduction in foods). Improving access to basic health services, particularly in low — and middle-income countries. The promotion of healthy lifestyles through awareness-raising campaigns on nutrition and physical activity. Implementation of Screening programs for the early detection of risk factors such as hypertension and Diabetes. Strengthening health systems to ensure a high quality treatment of patients with CVD. Summary Cardiovascular diseases remain one of the biggest health challenges of the present. The data of the WHO, not only to their high mortality and morbidity rate, but also the unequal distribution between different regions and socio-economic groups. Effective control of these diseases requires a combined effort at the global, national and local level — including prevention, early detection and adequate therapy. If you want, I can make certain sections in more detail, or other statistical data to add!
A sedentary lifestyle, alcohol, and cigarette consumption increase body weight which in turn hinders healthy blood circulation and strength of arteries and veins. This results in high blood pressure. So, if you’re overweight, you need to monitor your blood pressure frequently. Cardiovascular diseases, the who data. Ang mga modernong gamot sa pag-imprenta ay hinahati sa 10 iba't ibang grupo ayon sa kanilang mekanismo ng pagkilos. Pagkatapos suriin ng doktor ang mga reklamo ng pasyente at ang resulta ng mga pagsusuri, nagrereseta siya ng isa o higit pang gamot, na hindi dapat baguhin nang mag-isa. Ang mga gamot sa puso at daluyan ng dugo ay hindi kabilang sa mga puwedeng irekomenda sa kaibigan. Ang maling desisyon ay maaaring magdulot ng malungkot na kahihinatnan. Lahat ng gamot na pampababa ng presyon ng dugo ay kailangan ng reseta. Sa artikulong ito, tinitingnan natin ang kanilang modernong klasipikasyon base sa mga aktibong sangkap at sa paraan ng epekto nito sa katawan.
The risk of death from cardiovascular disease
Medicines for high blood pressure pressure
Prevention of cardiovascular disease project
The best of modern medicines for high blood pressure
https://holodprof.net/articles/47810-altai-key-herbs-for-high-blood-pressure.html
https://demo.atlantisweb.ru/articles/13550-prevention-of-cardiovascular-diseases.html
Minsan lang na biglaang pagtaas ng presyon o bahagyang mataas na resulta ay hindi palaging nangangailangan ng agarang pag-inom ng tableta. Lahat ng rekomendasyon ng mga espesyalista at ang mga magagamit na paraan ng pag-iwas ay mukhang simple lang, pero sa aktwal na buhay, ang maingat na pag-aalaga sa kalusugan ng dugo at sistema ng puso ay nakakaiwas sa biglaan at sobrang hindi kanais-nais na pagtaas ng presyon. Diuretiko (Diuretika) ay nagpapataas ng pag-ihi ng katawan, na nagreresulta sa pagbaba ng presyon ng dugo. Simpleng paliwanag: Ang tuloy-tuloy na pag-ihi ng katawan ay nagdudulot ng pagbaba ng dami ng plasma sa dugo at sa gayon ay mas kaunting likido sa mga ugat — bumababa ang presyon sa mga pader ng ugat.
Edarbi (Azilsartan) as a modern treatment option for high blood pressure Hypertension medical arterial hypertension referred to, is one of the most common chronic diseases worldwide and is a major risk factor for cardiovascular complications such as heart attack, stroke, and kidney disease. The effective reduction in blood pressure is therefore a key target in the prevention of this life-threatening consequences. Mechanism of action of Edarbi Edarbi contains the active ingredient Azilsartan Medoxomil belongs to the group of Angiotensin II receptor blocker (ARB, also AT₁ receptor antagonists called). The mechanism of action is based on the selective and competitive Blockade of the AT₁ receptors, to the vasoconstrictor Angiotensin II binds. Through this inhibition, the following effects can be triggered: Vasodilation (Vascular Dilation), Reduction in Aldosterone secretion, Decrease of peripheral vascular resistance, Lowering of blood pressure. In contrast to ACE inhibitors Azilsartan does not cause significant accumulation of Bradykinin, which is associated with a lower incidence of side effects, such as the typical dry cough. Clinical Efficacy Several randomized controlled trials (RCTs) have demonstrated the efficacy of Azilsartan in patients with mild-to-moderate hypertension. In an important study, it was shown that Edarbi achieved a significantly greater reduction in systolic and diastolic blood pressure compared to other ARBs (eg, Valsartan). The reduction in blood pressure remains stable for 24 hours, what time of Azilsartan (about 11 hours) and the high affinity of the AT₁ Receptor is due to the long half‑explained. Dosage and administration Diefangsdosierung of Edarbi is typically 40 mg once daily. In case of insufficient blood pressure control, the dose can be increased to two to four weeks to 80 mg. The intake is independent of meals possible. In patients with mild to moderate renal impairment no dose adjustment is required; in the case of severe renal impairment or in patients on dialysis, Edarbi should be used with caution. Side effects and contraindications The most common side effects of Edarbi: Headache, Dizziness, increased levels of Potassium (Hyperkalieämie), Renal function disorders (rare). Contraindicated Edarbi is: known Hypersensitivity to the active substance, severe liver disease, bilateral renal artery stenosis, during pregnancy and lactation (teratogenic potential). Conclusion Edarbi (Azilsartan), due to its high efficacy, good tolerability, and long-lasting reduction in blood pressure is a valuable Option in the treatment of arterial hypertension. In particular, for patients, the ACE inhibitor is not tolerated because of adverse side effects, the active ingredient an effective Alternative. An individual Benefit-risk assessment, taking into account the patient's history, however, is always required.